Analysts Set Cellebrite DI Ltd. (NASDAQ:CLBT) Price Target at $21.40

Cellebrite DI Ltd. (NASDAQ:CLBT) has been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $21.40.

A number of equities analysts have commented on CLBT shares. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. DA Davidson started coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th.

Insider Buying and Selling

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 13,269 shares of company stock worth $169,592 over the last quarter. 5.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. increased its position in shares of Cellebrite DI by 91.1% during the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock valued at $105,000 after acquiring an additional 3,626 shares during the last quarter. Alpine Woods Capital Investors LLC acquired a new stake in shares of Cellebrite DI during the first quarter valued at about $223,000. Evolutionary Tree Capital Management LLC increased its position in shares of Cellebrite DI by 22.6% during the first quarter. Evolutionary Tree Capital Management LLC now owns 183,473 shares of the company’s stock valued at $2,528,000 after acquiring an additional 33,829 shares during the last quarter. Ashford Capital Management Inc. increased its position in shares of Cellebrite DI by 5.5% during the first quarter. Ashford Capital Management Inc. now owns 1,762,937 shares of the company’s stock valued at $24,293,000 after acquiring an additional 92,092 shares during the last quarter. Finally, Quantinno Capital Management LP acquired a new stake in shares of Cellebrite DI during the first quarter valued at about $150,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $12.83 on Tuesday. The firm’s 50-day moving average is $13.12 and its two-hundred day moving average is $14.91. Cellebrite DI has a 12 month low of $11.02 and a 12 month high of $19.98. The company has a market capitalization of $3.20 billion, a PE ratio of 45.82, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.